Skip to content

Psilocybin: all studies

Page 122 of 440: studies 1,211 to 1,220 of 4,399, newest first. Back to the psilocybin overview

Research

The development of psilocybin therapy for treatment-resistant depression: an update

BJPsych Bulletin June 26, 2023 Anya Borissova, James J. Rucker 16 citations

Summary Psilocybin is a classic psychedelic drug that has attracted increasing research interest over the past 10 years as a possible treatment for mood, anxiety and related conditions. Initial phase 2 clinical trials of psilocybin given alongside psychological support for major depression and treatment-resistant depression (TRD) demonstrated encouraging signs of basic safety, further confirmed...

DOI: 10.1192/bjb.2023.25 (opens in new tab) Full text (opens in new tab) Depressive disorders Education and training Individual psychotherapy Novel cns drugs +6

Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data

Journal of Psychoactive Drugs June 22, 2023 Bheatrix Bienemann, Amanda Rocha Barbosa, Lucas Villar Magalhães da Cruz et al. 3 citations

There has been growth in the use of psychedelics by the global population in recent years. In addition to recreational and ritualistic use, recent research into psychedelics has brought advances for treating mental disorders. Understanding the specific circumstances in which psilocybin leads to positive outcomes may have important implications for the future of its clinical use and for harm...

Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats

Frontiers in Neuroscience June 22, 2023 Filip Tylš, Čestmír Vejmola, Vlastimil Koudelka et al. 9 citations

Introduction Psilocybin is one of the most extensively studied psychedelic drugs with a broad therapeutic potential. Despite the fact that its psychoactivity is mainly attributed to the agonism at 5-HT 2A receptors, it has high binding affinity also to 5-HT 2C and 5-HT 1A receptors and indirectly modulates the dopaminergic system. Psilocybin and its active metabolite psilocin, as well as other...

“Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli”

Biotechnology and Bioengineering June 20, 2023 Jessica E. Flower, William J Gibbons, Alexandra M. Adams et al. 26 citations

Abstract Traditional psychedelics are undergoing a transformation from recreational drugs, to promising pharmaceutical drug candidates with the potential to provide an alternative treatment option for individuals struggling with mental illness. Sustainable and economic production methods are thus needed to facilitate enhanced study of these drug candidates to support future clinical efforts....

DOI: 10.1002/bit.28480 (opens in new tab) Psilocybin Co-cultures Enzyme promiscuity Tryptamine +6

A case-study evaluation of the “Copenhagen Music Program” for psilocybin-assisted therapy

Frontiers in Psychology June 16, 2023 Gina Ratkovic, Mike Sosteric, Tristan Sosteric 8 citations

In a recent article, Messell and colleagues provide a curated list, the “Copenhagen Music Program for Psilocybin”. We test their music program with an experienced Indigenous therapist/psychonaut on a 3.5 gram psilocybin journey. Based on comments provided by the Indigenous therapist, we find the program contains musical choices that evoke specific colonial and religious contexts. We also find...

DOI: 10.3389/fpsyg.2023.1156852 (opens in new tab) Case reports Guided imagery Music-informed psychedelic therapy Psycholytic therapy +4

Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin – A retrospective case study

June 9, 2023 Mika Turkia 3 citations preprint

This article presents the case of a young woman in her mid-twenties with a history of depression since childhood. She lived with a mother who failed to take care of her. The patient cared for the emotional needs of the mother instead of the mother caring for the daughter's needs. Her father was mostly absent. Already around the age of thirteen, the patient was severely depressed and was...

Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study

June 9, 2023 Sandeep M. Nayak, Sydney H White, Samantha Hilbert et al. 1 citation preprint

Recent studies suggest psychedelic use may be associated with changes in a variety of beliefs or belief-like states, including increased 1) mind perception, 2) non-naturalistic beliefs, and 3) Atheist-Believer status (e.g., believer, agnostic, or non-believer). We conducted a prospective longitudinal study among participants (N = 657) who planned to have a psychedelic experience. We asked...

DOI: 10.31234/osf.io/auycp_v1 (opens in new tab) Psilocybin Naturalism Naturalistic observation Perception +2

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

Journal of Psychopharmacology June 8, 2023 Natalie Gukasyan, Roland R. Griffiths, David B. Yaden et al. 60 citations

Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggest that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period. Aims: To learn the extent to which antidepressants may diminish the effects of psilocybin-containing mushrooms both...

Cardioprotective Potential of the Ethanol and Water Extracts of Four Psilocybin Mushrooms on Angiotensin II-Induced Hypertrophy and Oxidative Stress on H9C2 Cardiomyocytes

Preprints.org June 6, 2023 Sanah Malomile Nkadimeng, Christiaan M.l. Steinmann, J.n. Eloff 1 citation preprint

Psilocybin-containing mushrooms, commonly known as magic mushrooms have antidepressant effect, however, their safety in cardiovascular diseases such as heart failure is not fully known and needs to be investigated. Cardiac hypertrophy is an independent risk factor for heart failure morbidity and mortality. Angiotensin II (Ang-II) plays a major role in the pathogenesis of cardiac hypertrophy. We...

DOI: 10.20944/preprints202306.0362.v1 (opens in new tab) Angiotensin ii Oxidative stress Losartan Reactive oxygen species +3

Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis.

Psychology of Addictive Behaviors June 5, 2023 Gabrielle Agin-Liebes, Elizabeth M. Nielson, Michael Zingman et al. 42 citations

OBJECTIVE: The primary aim of this qualitative study was to delineate psychological mechanisms of change in the first randomized controlled trial of psilocybin-assisted psychotherapy to treat alcohol use disorder (AUD). Theories regarding psychological processes involved in psychedelic therapy remain underdeveloped. METHOD: Participants (N = 13) mostly identified as non-Hispanic and White, with...

DOI: 10.1037/adb0000935 (opens in new tab) Psychedelic therapy Addiction treatment Mental health Substance abuse recovery +1